Diagnostics company Astute Medical Inc has completed a $26.5m Series B financing co-led by Domain Associates and Delphi Ventures.
The company focuses on the diagnosis of diseases – such as acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis – that require rapid risk assessment.
Christopher Hibberd, Astute Medical CEO, said, “We are pleased with the strong investor interest, which demonstrates confidence in our approach to improving the diagnosis of critical conditions in hospital settings. With this financing, the resources are in place to conduct clinical studies…”
Astute will use the funding to advance research and development aimed at the identification and validation of protein biomarkers with the goal of commercialising its diagnostic products.
Copyright © 2010 AltAssets